Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Diagnostics Aims to Detect DNA in Patient Samples

By Labmedica staff writers
Posted on 13 Feb 2008
Molecular diagnostics aims to provide faster and more sensitive alternatives to traditional microbiology tests and immunoassays by detecting molecules of DNA from bacteria, viruses, and cancer cells in patient samples.

Simple automated solutions will be found to replace time-consuming, labor-intensive tests for infectious diseases and cancer in routine hospital laboratories. More...
Results will become available to physicians much more quickly--in hours rather than days or weeks--and patients will be able to receive treatment sooner.

Beckman Coulter (Galway, Ireland) has launched a four-year collaboration with the National University of Ireland (NUI; Galway, Ireland) in the hope of speeding up molecular diagnostic tests. The Irish Government helped set up the agreement and is hoping that it could lead to further investment from Beckman Coulter.

The Beckman facility in Ireland makes a variety of chemistry, hematology, and immunoassay reagent products that can be used in conjunction with the company's diagnostic products. It is the largest of the company's four similar manufacturing facilities across Europe.

"The agreements give us access to intellectual property for the development of tests for infectious diseases including sepsis, hospital-acquired infections, and sexually transmitted diseases, such as those caused by Chlamydia and Neisseria,” said Mike Whelan, group vice president of Beckman Coulter's high sensitivity testing group.

The University's National Center for Biomedical Engineering Science (NCBES; Galway, Ireland) and the microbiology department (Galway, Ireland) will lead the initiative. A team of 10 Masters and Ph.D. scientists based at the university will be created to build on intellectual property already developed there. The field is thought to be potentially worth US$2 billion annually.


Related Links:
Beckman Coulter
National University of Ireland
National Center for Biomedical Engineering Science (NUI)

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.